Terms: = Uterine cancer AND CCDC6, D10S170, 8030, ENSG00000108091, Q16204, TPC, H4, TST1 AND Treatment
24 results:
1. Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician's choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer.
Yonemori K; Fujiwara K; Hasegawa K; Yunokawa M; Ushijima K; Suzuki S; Shikama A; Minobe S; Usami T; Kim JW; Kim BG; Wang PH; Chang TC; Yamamoto K; Han S; McKenzie J; Orlowski RJ; Miura T; Makker V; Man Kim Y
J Gynecol Oncol; 2024 Mar; 35(2):e40. PubMed ID: 38302725
[TBL] [Abstract] [Full Text] [Related]
2. Down-regulation of human papillomavirus E6 oncogene and antiproliferative effect of Schisandra chinensis and Pueraria lobata natural extracts on Hela cell line.
Cardona-Mendoza A; Fonseca-Benitez A; Buitrago DM; Coy-Barrera E; Perdomo SJ
J Ethnopharmacol; 2024 Jan; 319(Pt 3):117225. PubMed ID: 37797877
[TBL] [Abstract] [Full Text] [Related]
3. Health-Related Quality of Life in Patients With Advanced Endometrial cancer Treated With Lenvatinib Plus Pembrolizumab or treatment of Physician's Choice.
Lorusso D; Colombo N; Herraez AC; Santin AD; Colomba E; Miller DS; Fujiwara K; Pignata S; Baron-Hay SE; Ray-Coquard IL; Shapira-Frommer R; Kim YM; McCormack M; Massaad R; Nguyen AM; Zhao Q; McKenzie J; Prabhu VS; Makker V
Eur J Cancer; 2023 Jun; 186():172-184. PubMed ID: 37086595
[TBL] [Abstract] [Full Text] [Related]
4. An integrative pan cancer analysis of RET aberrations and their potential clinical implications.
Zhou L; Li J; Zhang X; Xu Z; Yan Y; Hu K
Sci Rep; 2022 Aug; 12(1):13913. PubMed ID: 35978072
[TBL] [Abstract] [Full Text] [Related]
5. Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: Results from Study 309/KEYNOTE-775.
Yonemori K; Yunokawa M; Ushijima K; Sakata J; Shikama A; Minobe S; Usami T; Enomoto T; Takehara K; Hasegawa K; Yamagami W; Yamamoto K; Han S; Dutta L; Orlowski R; Miura T; Makker V; Fujiwara K
Cancer Sci; 2022 Oct; 113(10):3489-3497. PubMed ID: 35612971
[TBL] [Abstract] [Full Text] [Related]
6. SIRT1 and gynecological malignancies (Review).
Chen J; Chen H; Pan L
Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649834
[TBL] [Abstract] [Full Text] [Related]
7. Role of B7-H4 in the Progression and Prognosis of Cervical Inflammation to cancer After Human Papilloma Virus Infection.
Qiu F; Yuan C; Xu J; Zhang J; Chen F; Liu D; Zheng B; Li R; Huang X; Xu J
J Biomed Nanotechnol; 2019 May; 15(5):1043-1051. PubMed ID: 30890234
[TBL] [Abstract] [Full Text] [Related]
8. Therapy of cervical cancer using
Li W; Sun D; Li N; Shen Y; Hu Y; Tan J
J Int Med Res; 2018 Jun; 46(6):2359-2370. PubMed ID: 29658363
[TBL] [Abstract] [Full Text] [Related]
9. Histone deacetylase inhibitor, Romidepsin (FK228) inhibits endometrial cancer cell growth through augmentation of p53-p21 pathway.
Li LH; Zhang PR; Cai PY; Li ZC
Biomed Pharmacother; 2016 Aug; 82():161-6. PubMed ID: 27470351
[TBL] [Abstract] [Full Text] [Related]
10. B7-H3, B7-H4, Foxp3 and IL-2 expression in cervical cancer: Associations with patient outcome and clinical significance.
Huang C; Zhou L; Chang X; Pang X; Zhang H; Zhang S
Oncol Rep; 2016 Apr; 35(4):2183-90. PubMed ID: 26848032
[TBL] [Abstract] [Full Text] [Related]
11. Tissue inhibitor of metalloproteinases-4 (TIMP-4) regulates stemness in cervical cancer cells.
Lizarraga F; Espinosa M; Ceballos-Cancino G; Vazquez-Santillan K; Bahena-Ocampo I; Schwarz-Cruz Y Celis A; Vega-Gordillo M; Garcia Lopez P; Maldonado V; Melendez-Zajgla J
Mol Carcinog; 2016 Dec; 55(12):1952-1961. PubMed ID: 26618609
[TBL] [Abstract] [Full Text] [Related]
12. Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy.
Vanderstraeten A; Luyten C; Verbist G; Tuyaerts S; Amant F
Cancer Immunol Immunother; 2014 Jun; 63(6):545-57. PubMed ID: 24658839
[TBL] [Abstract] [Full Text] [Related]
13. Chromatin composition alterations and the critical role of MeCP2 for epigenetic silencing of progesterone receptor-B gene in endometrial cancers.
Chu Y; Wang Y; Zhang G; Chen H; Dowdy SC; Xiong Y; Liu F; Zhang R; Li J; Jiang SW
Cell Mol Life Sci; 2014 Sep; 71(17):3393-408. PubMed ID: 24531693
[TBL] [Abstract] [Full Text] [Related]
14. DNA methylation-independent reversion of gemcitabine resistance by hydralazine in cervical cancer cells.
Candelaria M; de la Cruz-Hernandez E; Taja-Chayeb L; Perez-Cardenas E; Trejo-Becerril C; Gonzalez-Fierro A; Chavez-Blanco A; Soto-Reyes E; Dominguez G; Trujillo JE; Diaz-Chavez J; Duenas-Gonzalez A
PLoS One; 2012; 7(3):e29181. PubMed ID: 22427797
[TBL] [Abstract] [Full Text] [Related]
15. A pilot study of combination chemotherapy with paclitaxel, pirarubicin, and carboplatin (tpc) for endometrial carcinoma.
Hongo A; Kusumoto T; Nakamura K; Seki N; Kodama J; Hiramatsu Y
Int J Clin Oncol; 2010 Oct; 15(5):476-83. PubMed ID: 20526888
[TBL] [Abstract] [Full Text] [Related]
16. A natural histone deacetylase inhibitor, Psammaplin A, induces cell cycle arrest and apoptosis in human endometrial cancer cells.
Ahn MY; Jung JH; Na YJ; Kim HS
Gynecol Oncol; 2008 Jan; 108(1):27-33. PubMed ID: 17920664
[TBL] [Abstract] [Full Text] [Related]
17. Histone deacetylase inhibitor apicidin downregulates DNA methyltransferase 1 expression and induces repressive histone modifications via recruitment of corepressor complex to promoter region in human cervix cancer cells.
You JS; Kang JK; Lee EK; Lee JC; Lee SH; Jeon YJ; Koh DH; Ahn SH; Seo DW; Lee HY; Cho EJ; Han JW
Oncogene; 2008 Feb; 27(10):1376-86. PubMed ID: 17828306
[TBL] [Abstract] [Full Text] [Related]
18. Apicidin, a novel histone deacetylase inhibitor, has profound anti-growth activity in human endometrial and ovarian cancer cells.
Ueda T; Takai N; Nishida M; Nasu K; Narahara H
Int J Mol Med; 2007 Feb; 19(2):301-8. PubMed ID: 17203205
[TBL] [Abstract] [Full Text] [Related]
19. CBHA is a family of hybrid polar compounds that inhibit histone deacetylase, and induces growth inhibition, cell cycle arrest and apoptosis in human endometrial and ovarian cancer cells.
Takai N; Ueda T; Nishida M; Nasu K; Matsuda K; Kusumoto M; Narahara H
Oncology; 2006; 70(2):97-105. PubMed ID: 16601366
[TBL] [Abstract] [Full Text] [Related]
20. A novel histone deacetylase inhibitor, Scriptaid, induces growth inhibition, cell cycle arrest and apoptosis in human endometrial cancer and ovarian cancer cells.
Takai N; Ueda T; Nishida M; Nasu K; Narahara H
Int J Mol Med; 2006 Feb; 17(2):323-9. PubMed ID: 16391833
[TBL] [Abstract] [Full Text] [Related]
[Next]
